Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex in Ataxia-Telangiectasia
2023-509077-23-00Phase 3Completed
- Sponsor
- IRulya Therapeutics
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone sodium phosphate in ataxia-telangiectasia (AT) (2 arms), sponsored by IRulya Therapeutics. Primary endpoint: Change in RmICARS from baseline to Visit 9 (Day 168). Started Apr 2024; status: completed.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on 2023-509077-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509077-23-00.